Current Edition

Ajaz Hussain and Wuxi Apptec’s Dr Minzhang Chen join 12 strong CPhI Annual Industry report experts

2016 report topics include 3D printing, FDA quality metrics, contract services, pharma growth in China and India, and generic licensing
The CPhI Expert Panel members for 2016 are:
Gil Roth, President at PBOA
Alan Sheppard, Principal, Global Generics at IMS Health
Vivek Sharma, CEO at Piramal Enterprises Ltd.
Ajaz Hussain, Founder CEO at Insight Advice & Solutions LLC
Dr Minzhang Chen, CEO at STA Pharma (Wuxi Apptec)
Dilip Shah, CEO at Vision Consulting Group
Prabir Basu, Pharma Manufacturing and Regulations Consultant
Brian Carlin, Director Open Innovation at FMC
Emil Cuirczak, President at Doramaxx Consulting
Bikash Chatterjee, President and CSO at PharmTech Associates
Girish Malhotra, President at EPCOT International
Ravi Limaye, President, Marketing at Biocon
Amsterdam, 06 September 2016: CPhI Worldwide, organized by UBM EMEA, announces the 2016 expert panel for the eagerly awaited CPhI Worldwide Annual Industry Report (4th edition) – to be released September and October 2016, in three parts. The report is a comprehensive and critically important publication that analyses key trends and innovations forecast by a panel of world class experts. Running as a series of opinions and articles, the CPhI experts call upon their collective 200+ years of commercial and technical acumen to prophesise the future direction, technologies, opportunities and threats in pharma. It’s an essential read for executives who wish to get a head start today on the shape of tomorrow’s industry.
This year, the CPhI Annual Report will see ten experts returning from 2015, along with two new valuable additions: Ajaz Hussain, Founder and CEO at Insight Advice & Solutions LLC (also the current president of NIPTE) and Dr Minzhang Chen, CEO of STA Pharmaceuticals – the API development and manufacturing division of Wuxi Apptec.
Dr Minzhang Chen is known globally in the pharmaceutical and biopharmaceutical industry and has over 18 years of experience in Process R&D and API Manufacturing. STA pharmaceutical is the leading China based CDMO and is a standard bearer of emerging research in China and globally.
Ajaz Hussain is a widely recognized leader within pharmaceuticals and drug development, having previously worked at the FDA, Wockhardt and Sandoz. He is an internationally renowned thought leader on pharmaceutical manufacturing, research and harmonisation – he served as the FDAs ICH lead, expediting the progress and implementation of ICH Q8, Q9 and Q10.
The 2016 report will provide an overview of contract services growth, predictions on continuous processing and 3D printing of finished formulations. Brian Carlin of FMC will look at the role of excipients, whilst Prabir Basu will explore new types of FDA quality metrics. Generics are also a central part of two expert contributions – from Alan Sheppard and Dilip Shah – with overall growth and licensing trends analysed. Additionally, Bikash Chatterjee will explain the how the management of data and information in pharma will be key to defining the industry in the next decade.
The Chinese and Indian global pharma economies continue to drive growth, and representatives from Piramal, Biocon and Wuxi Apptec will examine factors affecting the markets in the next 2-5 years.
“This year’s annual report features over 200+years of high level pharma expertise providing unparalleled insights into global trends, issues and challenges over the short and medium term. The panel provides a balanced view of experts from independent consultants and representatives from all the major pharma economies.
As the pharma industry continues to globalise and new technologies emerge, access to information on how to implement new methods and development will become increasingly business critical to both pharma and supply side companies. Our annual report is released to help the industry stay informed, to stimulate debate and collaborations, and more quickly develop the pharmaceutical products of tomorrow”, commented Chris Kilbee, Group Director Pharma at UBM EMEA.
The CPhI 2016 Annual Report is available for download, along with other Pharma Insights Reports, at: